该行指出，主动脉支架业务部门的胸腔/腹腔主动脉支架在终端用户层面分别降价约40%，以及20%至35%，预期心脉医疗承受了大部分的冲击，将转化为其出厂价格下降25%至30%。不过，该行指心脉医疗改善营运效率方面的努力将有助长期利润率，将长期净利润率预测由23%大幅上调至约30%。因此，该行亦相应上调微创医疗长期净利润率预测，由原先11%向上修订至12%。Microport (00853) rose nearly 8% intraday and as of the time of publication, it increased by 4.1% to HK$6.86 with a turnover of 96.2774 million Hong Kong dollars.
According to the AI Finance app, Microport (00853) rose nearly 8% intraday and as of the time of publication, it increased by 4.1% to HK$6.86 with a turnover of 96.2774 million Hong Kong dollars.
On the news front, Microport announced the performance of Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. in the first 9 months of 2024, with revenue of approximately 0.97 billion yuan, a year-on-year increase of 9.13%; the net income attributable to shareholders of Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. was approximately 0.553 billion yuan, a year-on-year increase of 42.46%. Morgan Stanley published a report stating that after the performance announcement of the affiliated Shanghai Microport Endovascular Medtech(Group)Co.,Ltd., the target price for Microport's H shares has been raised from 7.5 yuan to 7.8 yuan with a "shareholding" rating.
The bank pointed out that the aortic stent business department has reduced prices by about 40% at the end user level for thoracic/abdominal aortic stents, as well as 20% to 35%, expecting that Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. has borne most of the impact, which will translate into a 25% to 30% decrease in its ex-factory prices. However, the bank mentioned that Shanghai Microport Endovascular Medtech(Group)Co.,Ltd.'s efforts to improve operational efficiency will help long-term profit margins, with the long-term net income margin forecast being significantly revised from 23% to approximately 30%. Therefore, the bank has correspondingly raised the long-term net income margin forecast for Microport from the original 11% to a revised 12%.
